- Home
- BPOP vs ABVX Comparison
BPOP vs ABVX Comparison
Compare BPOP & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BPOP | ABVX |
|---|---|---|
| Founded | 1893 | 2013 |
| Country | United States | France |
| Employees | 9406 | 67 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 10.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BPOP | ABVX |
|---|---|---|
| Price | $130.92 | $116.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $148.60 | $128.42 |
| AVG Volume (30 Days) | 473.9K | ★ 698.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.33 | N/A |
| Revenue Next Year | $6.02 | $0.22 |
| P/E Ratio | $11.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $78.23 | $4.77 |
| 52 Week High | $149.31 | $148.83 |
Technical Indicators
Market Signals| Indicator | BPOP | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 48.81 |
| Support Level | $122.73 | $106.37 |
| Resistance Level | $149.23 | $131.27 |
| Average True Range (ATR) | 4.44 | 5.21 |
| MACD | -1.61 | -0.67 |
| Stochastic Oscillator | 24.89 | 41.53 |
Price Performance
Historical ComparisonAbout BPOP Popular Inc.
Popular Inc, based in Puerto Rico, is a financial holding company with four main subsidiaries: Banco Popular de Puerto Rico, a bank in Puerto Rico in terms of assets; Banco Popular North America, its banking operation in the continental United States; Evertec, a data processor; and Popular Financial Holdings, a diversified financial services company. The Corporation's reportable segments consist of Banco Popular de Puerto Rico and Popular U.S.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.